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Abstract
Objective: Products of intracellular mevalonate metabolism are essential for cell growth and
proliferation. Inhibition of mevalonate synthesis by statins has been shown to suppress mesangial
cell proliferation associated with various glomerular diseases. In this study, we investigated the
effect of a new synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, NK-104, on
cultured rat mesangial cell proliferation.
Methods: The cultured rat mesangial cells were stimulated by 10% fetal calf serum or platelet-
derived growth factor in the absence or presence of NK-104 and mevalonate metabolites. 5-bromo-
2-deoxyuridine incorporation was used to assess DNA synthesis. In other experiments, Ras
processing and mitogen-activated protein kinase activation were analyzed by Western blotting.
Results: NK-104 inhibited fetal calf serum- or platelet-derived growth factor-stimulated Ras
processing and mitogen-activated protein kinase activation. NK-104 also caused inhibition of fetal
calf serum- or platelet-derived growth factor-stimulated 5-bromo-2-deoxyuridine incorporation and
cell proliferation. Mevalonic acid, farnesyl pyrophosphate, and geranylgeranyl pyrophosphate
significantly prevented these inhibitory effects of NK-104.
Conclusions: The present results suggest that NK-104, by inhibiting the synthesis of isoprenoid
metabolites of mevalonate, may modulate Ras-mediated signaling events associated with mesangial
cell proliferation.
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NK-104 and cell proliferation
INTRODUCTION
Proliferation of mesangial cells and accumulation of
mesangial extracellular matrix are principal histo-
pathological findings seen in various human and
experimental renal diseases. Recent studies clearly
demonstrated the important role of mesangial cell
proliferation in subsequent matrix expansion in the
glomeruli. Many mitogens, including platelet-derived
growth factor (PDGF), have been implicated in the
proliferation of glomerular cells, and action of these
mitogens on intracellular signals and gene transcription
occurs in many cases through the Ras superfamily of
small monomeric guanosine triphosphatases (1,2).
Therefore, targeting of Ras proteins is a theoretically
attractive strategy in the control of proliferation of
various cells such as mesangial and tubular cells.
Inhibiting production of mevalonate by 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase
inhibitors has been reported to suppress activation of Ras
and mitogen-activated protein (MAP) kinase, and
proliferation of several cell types. The antiproliferative
effect is associated with a reduction of prenylated Ras
(3,4). Alterations in the production of farnesyl pyro-
phosphate (FPP) and geranylgeranyl pyrophosphate
(GGPP), two important isoprenoid intermediates, have
been implicated in this process (5-7). In this study, NK-
104, a newly developed HMG-CoA reductase inhibitor,
was used to investigate its effect on the Ras processing,
activation of MAP kinase, and cell proliferation in
cultured rat mesangial cells. Furthermore, studies were
also designed to identify the mevalonate metabolites




NK-104 was obtained from Kowa Co. Ltd. (Nagoya,
Japan. Platelet-derived growth factor was obtained from
Genzyme/Techne (MPTS, Minnesota, US). Fetal calf
serum (FCS) was obtained from GIBCO BRL (Grand
Island, New York, US), mevalonic acid and GGPP were
purchased from ICN Biomedicals (Aurora, Ohio, US),
and FPP was obtained from Alexis Biochemicals (San
Diego, California, US).
Isolation of glomeruli and mesangial cell
culture
Rat mesangial cells were isolated and grown in culture
using a modification of a previously reported method (8).
Briefly, glomeruli from 100- to 150-g male Sprague-
Dawley rats (Japan Charles River, Kanagawa, Japan)
were obtained by sequential sieving of renal cortical tissue
through stainless steel screens. After treatment with
trypsin-ethylenediaminetetraacetic acid and collagenase
IV, the glomeruli were washed and resuspended in culture
medium (Roswell Park Memorial Institute [RPMI] 1640
supplemented with FCS 20%, penicillin 100 U/mL,
streptomycin 100 mg/mL, glutamine 2 mM, bovine
insulin 5 µg/mL, and human transferrin 5 µg/mL) and
plated onto 10-cm culture dishes. Culture dishes were
incubated in a humidified 5% CO2, 95% air incubator at
37oC. At confluence, cells were passaged by incubation
with trypsin-ethylenediaminetetraacetic acid. For the
present experiments, mesangial cells between the 4 to 10
passages were used. Mesangial cells were identified from
their characteristic morphological and immuno-
cytochemical features (9). In brief, cultured cells were
identified as mesangial cells by their spindle shape in
phase contrast microscopy, and positive staining with
anti-actin, myosin, desmin, and vimentin antibodies, and
negative staining with anti-cytokeratin, factor VIII, and
common leukocyte antigen antibodies in immuno-
fluorescent microscopy (Fig. 1A and B). The cell viability
was measured by trypan blue exclusion (10).
Figure 1. Positive staining of vimentin in mesangial cells (A) and
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DNA synthesis and cell proliferation
experiments
DNA synthesis of mesangial cells was assayed by
measuring the incorporation of thymidine analogue 5-
bromo-2-deoxyuridine (BrdU) into the cells (11) by using
cell proliferation enzyme-linked immunosorbent assay
(ELISA) system II (Amersham Pharmacia Biotech UK
Limited, Buckinghamshire, UK). Mesangial cells were
seeded in 96-well culture plates at a density of 10 000
cells per well. At confluency, the cells were synchronized
to the quiescent state by incubation in serum-free RPMI
1640 for 48 hours. To study the effect of NK-104, the
cells were preincubated with NK-104 at the indicated
concentrations for 24 hours before the experiment. Then
the cells were exposed to RPMI 1640 containing FCS
10% or PDGF (20 ng/mL) to stimulate mitogenesis, and
some cells were also exposed to one of the following:
mevalonate (100 µM), FPP (10 µM), or GGPP (10 µM).
BrdU (20 µM) was added to all wells, and total BrdU
incorporation was measured over a 24-hour period. The
media were removed, and the cells were then fixed with
fixative solution for 30 minutes. After nonspecific
blocking of the site for 30 minutes, the mesangial cells
were incubated with peroxidase-labeled anti-BrdU
antibody at 37oC for 60 minutes. Incorporation of BrdU
into the mesangial cells was determined by absorbance
at 450 nm on an ELISA.
For determination of cell proliferation, the mesangial
cells were seeded into 24-well culture plates at a density
of 5000 cells per well. At about 60% confluency, the
cells were synchronized to quiescence as described
above. After 48 hours, the cells were exposed to RPMI
1640 containing FCS 10% or PDGF (20 ng/mL) in the
absence or presence of the agents listed above for 72
hours. Then the cell numbers were counted (4,12).
Ras processing and mitogen-activated
protein kinase assay
In separate experiments, to investigate whether inhibi-
tion of cell proliferation by NK-104 was caused by
suppression of Ras processing and MAP kinase
activation, we examined the effects of NK-104 on FCS-
or PDGF-stimulated Ras processing and MAP kinase
activation. Quiescent mesangial cells in culture dishes
were exposed to RPMI 1640 containing FCS 10% or
PDGF (20 ng/mL). NK-104-pretreated cells were also
exposed to one of the following: FPP (10 µM), GGPP
(10 µM), and mevalonate (100 µM). After 24 hours of
incubation, the media were removed, and the cells were
washed twice with cold phosphate buffered saline. The
cells were then harvested and lysed in lysis buffer (13).
After 30 minutes of incubation at 4oC, lysates were
centrifuged at 15 000 rpm at 4oC for 10 minutes. The
supernatant was saved and the protein concentration
was determined spectrophotometrically at 562-nm
absorbance with the bicinchoninic acid (BCA) protein
assay kit (Pierce Chemical, Rockford, IL, US). Samples
(30 µg) of proteins were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, and proteins
were immobilized by electrophoretic transfer to a
polyvinylidene fluoride membrane, and immunoblotted
using anti-pan-Ras antibody (Ab-2, oncogene) or anti-
MAP kinase antibody (Erk2, monoclonal; UBI, Lake
Placid, NY, US). Antibody reactions were visualized by
using peroxidase-conjugated goat antimouse immuno-
globulin G and an enhanced chemiluminescence
detection system (Amersham Corp., Buckingham shire,
England).
Results were expressed as mean ± standard deviation.
The significance of differences between the means of
groups was tested by using analysis of variance.
Differences were considered significant for a p value of
less than 0.05.
RESULTS
Effect of NK-104 on fetal calf serum or
platelet-derived growth factor-induced
DNA synthesis and cell proliferation
Platelet-derived growth factor or FCS caused a marked
stimulation of rat mesangial cell DNA synthesis, as
assessed by BrdU incorporation. NK-104 inhibited FCS-
or PDGF-induced DNA replication in a dose-dependent
manner (Fig. 2A and B). During 48 hours of incubation,
NK-104 did not alter the cell viability when compared
with control cells. The inhibitory effect of NK-104 on
DNA synthesis was completely prevented in the presence
of exogenous mevalonate (Fig. 2A and B). At each NK-
104 concentration, mevalonate maintained BrdU
incorporation at the control level observed in the cells
exposed only to FCS or PDGF. These results indicated
that the inhibition of DNA synthesis by NK-104 was
attributable to inhibition of HMG-CoA reductase rather
than toxic effects.
Exogenous FPP and GGPP reversed NK-104 inhibition
of DNA synthesis induced by FCS or PDGF, but the
degree of FPP reversal was dependent on that of NK-
104 inhibition in PDGF-stimulated mesangial cells. By
contrast to the results with FPP, the degree of GGPP
reversal was not dependent on that of NK-104 inhibition
(Fig. 3A and B).
The results of cell proliferation experiments paralleled
the results of BrdU incorporation. Exposure of quiescent
cells to FCS 10% or PDGF (20 ng/mL) caused a more
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than 20-fold increase in cell number over the 3-day study
period (Fig. 4A and B). NK-104 (20 µM) reduced cell
proliferation by -80%, and this effect was largely
prevented by exogenous mevalonate, or FPP and GGPP
in FCS-stimulated mesangial cells. However, in PDGF-
stimulated mesangial cells, FPP partly reversed the
inhibition of NK-104 on cell proliferation.
Effect of NK-104 on Ras processing and
mitogen-activated protein kinase
activation induced by fetal calf serum or
platelet-derived growth factor
The incubation of mesangial cells with NK-104 (20 µM)
decreased Ras processing and MAP kinase activation
induced by FCS. Coincubation of mesangial cells with
mevalonic acid (100 µM) eliminated NK-104-mediated
inhibition of Ras processing and MAP kinase activation
stimulated by FCS. Similarly, coincubation of mesangial
cells with FPP and GGPP partly reduced the effect of
NK-104 on Ras processing and MAP kinase activation
(Fig. 5A).
NK-104 also significantly inhibited Ras processing and
MAP kinase activation stimulated by PDGF. Mevalonic
acid (100 µM) and GGPP (10 µM) largely prevented NK-
104-mediated inhibition of Ras processing and MAP
kinase activation, but exogenous FPP (10 µM) did not
prevent NK-104-mediated inhibition of Ras processing
and MAP kinase activation (Fig. 5B).
DISCUSSION
Previous studies have demonstrated that inhibition of
HMG-CoA reductase, which blocks mevalonate syn-
thesis, also suppresses proliferation of mesangial cells
Figure 3. Effect of NK-104 on the DNA synthesis (24-hour BrdU
incorporation) in mesangial cells stimulated by FCS 10% (A) or
PDGF (20 ng/mL) (B). The results are mean ± SD of three
independent experiments each done in quadruplicate. Data are
expressed as a percentage of control mesangial cells exposed only
to FCS 10% or PDGF (20 ng/mL). FPP and GGPP were used at a
concentration of 10 µM.
*p≤0.01 versus FCS 10% or PDGF (20 ng/mL) alone.
FCS = fetal celf serum; FFP = farnesyl pyrophosphate; GGPP =
geranylgeranyl pyophosphate; PDGF = platelet-derived growth factor
A
B
Figure 2. DNA synthesis (24-hour BrdU incorporation) in mesangial
cells stimulated by FCS 10% (A) or PDGF (20 ng/mL) (B). The
results are mean (SD) of three independent experiments each done
in quadruplicate. Data are expressed as a percentage of control
mesangial cells exposed only to FCS 10% or PDGF (20 ng/mL).
Mevalonate was used at a concentration of 100 µM.
*p≤0.01 versus FCS 10% or PDGF (20 ng/mL) alone.
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(3,4,14). NK-104 has also been reported to suppress
intimal smooth muscle cell growth and extracellular
matrix production (15). Prevention of isoprenylation of
small guanosine triphosphatase-binding proteins may
be involved in these processes (16-18). Because the
activation of MAP kinase cascade seems to have a central
role in the integration and transmission of signaling
events (19,20), it is possible that the modulation of Ras
processing, and in turn regulation of MAP kinase
cascade, may have a primary impact on cell growth.
Because high-quality cultured human mesangial cells
could not be obtained, we used cultured rat mesangial
cells for this study. Any difference of the mesangial cell
proliferation mechanism between rats and humans is still
obscure. However, we considered that the cultured rat
mesangial cells used in this study did not exceed the
tolerance of the experiments. This study showed that NK-
104, a newly developed HMG-CoA reductase inhibitor,
caused dose-dependent reduction in mesangial cell DNA
synthesis. The degree of NK-104 inhibition of DNA
synthesis in this study was the same as that of lovastatin
in our preliminary study (unpublished data). It also
significantly decreased Ras processing and MAP kinase
activation induced by FCS or PDGF.
Additional studies were performed to identify
mevalonate metabolites that modulate the NK-104-
mediated Ras processing and activation of MAP kinase.
Coincubation of mesangial cells with mevalonic acid,
an immediate product of HMG-CoA reductase reaction,
Figure 5. Effect of NK-104 on the Ras processing and activation of
MAP kinase stimulated by FCS 10% (A) or PDGF (B). Cells were
treated with or without NK-104 (20 µM), mevalonate (100 µM), FPP
(10 µM), and GGPP (10 µM). Lane 1: FCS 10% (A) or PDGF (B)
alone; lane 2: NK-104; lane 3: NK-104 + mevalonate; lane 4: NK-
104 + FPP; lane 5: NK-104 + GGPP. The cells were lysed and lysates
were electrophoresed on sodium dodecyl sulfate-polyacrylamide
gel electrophoresis and immunoblotted with anti-pan-Ras or anti-
MAP kinase antibodies as described under Methods. Data are
representative of three independent experiments.
U = unprocessed form of Ras proteins; P = processed form of Ras
preteins; P-Mark = hyperphosphorylated MAP kinease.
A
B
Figure 4. Inhibition of FCS- or PDGF-induced mesangial cell
proliferation by NK-104. Quiescent mesangial cells were incubated
with NK-104 (20 µM) with stimulation by FCS 10% (A) or PDGF (20
ng/mL) (B) in the absence or presence of mevalonate (100 µM),
FPP (10 µM), and GGPP (1 µM) over a 3-day period. The results are
mean ± SD of three independent experiments each done in
quadruplicate. Data are expressed as a percentage of control
mesangial cells exposed only to FCS 10% or PDGF (20 ng/mL).
*p≤0.01 versus FCS 10% or PDGF (20 ng/mL) alone.
FCS = fetal celf serum; FFP = farnesyl pyrophosphate; GGPP =
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prevented the inhibition of DNA synthesis, Ras
processing, and activation of MAP kinase by NK-104.
Cellular mevalonate metabolism produced a series of
isoprenoid intermediates that, in turn, were converted
into particular end products necessary for cell growth
and proliferation. One critical end product of mevalonate
metabolism is cholesterol, which is required for cell
membrane synthesis and eventual cell growth in
proliferating cells. It might be argued that inhibition of
cholesterol synthesis was a possible mechanism by which
NK-104 reduced mesangial cell proliferation. Previous
studies have shown that the incubation of mesangial cells
with exogenous cholesterol or low density lipoprotein
did not alter HMG-CoA reductase inhibitor-induced
inhibition of DNA replication, activation of Ras and MAP
kinase (3,4,14). Results showed that the coincubation of
mesangial cells with FCS 10% (serving as an exogenous
source of cholesterol) did not prevent the inhibitory
effects of HMG-CoA reductase inhibitors on DNA
synthesis, Ras processing, and MAP kinase activation.
Taking these results together, it seems that the inhibition
of Ras processing, MAP kinase activation and
proliferation in the NK-104-treated mesangial cells may
result from inhibition of production of one or more iso-
prenoid intermediates of mevalonate metabolism rather
than cholesterol. Farnesyl pyrophosphate and GGPP are
two of the primary isoprenoid intermediates of mevalonic
acid metabolism implicated in isoprenylation of proteins
involved in cell growth (5-7,21). This study showed that
the addition of exogenous FPP or GGPP significantly
prevented NK-104-induced inhibition of Ras processing,
MAP kinase activity, and cellular proliferation induced by
FCS. However, the inhibition of PDGF-stimulated
mesangial cell proliferation was reversed only partly by
exogenous FPP, and FPP did not prevent inhibition of NK-
104-mediated Ras processing and MAP kinase activation.
In contrast, exogenous GGPP largely reversed the NK-104
inhibition of DNA synthesis, cell proliferation, Ras
processing, and MAP kinase activation. These results are
in agreement with a report that GGPP, rather than FPP,
might be the critical isoprenoid required for PDGF-
stimulated mesangial cell proliferation (6,22,23).
The present results and previous studies support the
hypothesis that NK-104, as well as other statins, by
suppressing production of isoprenoid, blocks Ras
processing and MAP kinase activation and downstream
nuclear signaling events, including the activation of
transcription factors and protooncogenes involved in
cellular DNA synthesis and growth. The antiproliferative
property of NK-104 on the mesangial cells raises the
possibility that it may suppress mesangial cell proliferation
and prevent subsequent development of matrix expansion
in progressive glomerular diseases in vivo.
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